<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035811</url>
  </required_header>
  <id_info>
    <org_study_id>QBGJ398-001</org_study_id>
    <nct_id>NCT04035811</nct_id>
  </id_info>
  <brief_title>Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)</brief_title>
  <official_title>Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QED Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QED Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term, multi-center, observational study in children 2.5 to 10 years with&#xD;
      achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications&#xD;
      and treatments of study participants. No study medication will be administered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized height velocity</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of natural history of achondroplasia symptoms in children with achondroplasia</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize achondroplasia symptoms in children with achondroplasia</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Achondroplasia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collect blood for central assessment of blood biomarkers&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children with achondroplasia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent by study participant or parent(s) or legally authorized&#xD;
             representative (LAR) and signed informed assent by the study participant (when&#xD;
             applicable)&#xD;
&#xD;
          -  Aged 2.5 to 10 years (inclusive) at study entry&#xD;
&#xD;
          -  Diagnosis of ACH&#xD;
&#xD;
          -  Ambulatory and able to stand without assistance&#xD;
&#xD;
          -  Study participants and parent(s) or LAR(s) are willing and able to comply with study&#xD;
             visits and study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have hypochondroplasia or short stature condition other than ACH (e.g trisomy 21,&#xD;
             pseudoachondroplasia, psychosocial short stature)&#xD;
&#xD;
          -  In females, having had their menarche&#xD;
&#xD;
          -  Height &lt; -2 or &gt; +2 standard deviations for age and sex based on reference tables on&#xD;
             growth in children with ACH&#xD;
&#xD;
          -  Annualized height growth velocity ≤1.5 cm/year over a period ≥6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Have a concurrent disease or condition that in the view of the Investigator and/or&#xD;
             Sponsor, may impact growth or where the treatment is known to impact growth.&#xD;
&#xD;
          -  Significant abnormality in screening laboratory results.&#xD;
&#xD;
          -  Have been treated with growth hormone, insulin-like growth factor 1 (IGF 1), or&#xD;
             anabolic steroids in the previous 6 months or long-term treatment (&gt;3 months) at any&#xD;
             time&#xD;
&#xD;
          -  Have received a C-type natriuretic peptide (CNP) analog or treatment targeting&#xD;
             fibroblast growth factor receptor (FGFR) inhibition at any time&#xD;
&#xD;
          -  Have had regular long-term treatment (&gt;1 month) with oral corticosteroids (low-dose&#xD;
             ongoing inhaled steroid for asthma is acceptable)&#xD;
&#xD;
          -  Have used any other investigational product or investigational medical device for the&#xD;
             treatment of ACH or short stature&#xD;
&#xD;
          -  Have had previous limb-lengthening surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>QED Therapeutics VP, Clinical Development</last_name>
    <role>Study Director</role>
    <affiliation>QED Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>QED Therapeutics</last_name>
    <phone>1-877-280-5655</phone>
    <email>PROPELstudyinfo@QEDTX.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Lynch</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>7217</phone_ext>
      <email>leslie.lynch@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Harmatz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Alfred I. Dupont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Norton</last_name>
      <phone>302-298-7978</phone>
      <email>michelle.norton@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Michael Bober, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Racheal Powers</last_name>
      <phone>513-803-1177</phone>
      <email>racheal.powers@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Howard Saal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LeeAnna Melton</last_name>
      <phone>615-343-6761</phone>
      <email>leeanna.melton@vumc.org</email>
    </contact>
    <investigator>
      <last_name>John Phillips, III, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook's Children Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Murdoch Children's Research Institute</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Choy</last_name>
      <phone>613 9936 6378</phone>
      <email>cassandra.choy@mcri.edu.au</email>
    </contact>
    <investigator>
      <last_name>Ravi Savarirayan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2H7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee-Ann Carroll</last_name>
      <phone>(780) 492 4902</phone>
      <email>lee-ann.carroll@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Peter Kannu, MB ChB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Femme Mere Enfant</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Nicolino</last_name>
      <phone>33 4 72 12 95 25</phone>
      <email>marc.nicolino@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Nicolino, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Couteau</last_name>
      <phone>+33 (0)5 67 77 13 69</phone>
      <email>couteau.n@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Pierre Salles, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vithas Hospital San Jose</name>
      <address>
        <city>Barcelona</city>
        <zip>08305</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Maria de Bergua Domingo</last_name>
      <phone>+34 650 806 071</phone>
      <email>josepmaria.debergua@ucatrauma.com</email>
    </contact>
    <investigator>
      <last_name>Jorge Knörr, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>24086</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vega Mauleon Martinez</last_name>
      <phone>+34912071876</phone>
      <email>vegamauleon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fernando Santos Simarro, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Leiva Gea</last_name>
      <phone>+34646568789</phone>
      <email>antonioleiva7@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Leiva Gea, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shane Roberts</last_name>
      <phone>+44 01173420177</phone>
      <email>shane.roberts@uhbristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Christine Burren, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vrinda Saraff</last_name>
      <phone>+44 121 333 9999</phone>
      <email>vrinda.saraff@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Vrinda Saraff, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen McDevitt</last_name>
      <phone>+44(0)776-542-2553</phone>
      <email>helen.mcdevitt@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Helen McDevitt, MB ChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Irving</last_name>
      <phone>+44 0 20 7188 7188</phone>
      <email>melita.irving@gstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Millgate</last_name>
      <email>kelly.millgate@gstt.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Melinda Irving, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester University Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayne Evans</last_name>
      <phone>+44 114 3053875</phone>
      <email>jayne.evans17@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Paul Arundel, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.QEDtx.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 20, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skeletal dysplasia</keyword>
  <keyword>Endochondral ossification</keyword>
  <keyword>ACH</keyword>
  <keyword>Shortened proximal limbs</keyword>
  <keyword>Fibroblast growth factor receptor 3</keyword>
  <keyword>FGFR3</keyword>
  <keyword>Endochondral bone formation</keyword>
  <keyword>Short-limb disproportionate dwarfism</keyword>
  <keyword>Bone disease</keyword>
  <keyword>Dwarfism</keyword>
  <keyword>Bone diseases</keyword>
  <keyword>Musculoskeletal diseases</keyword>
  <keyword>Osteochondrodysplasia</keyword>
  <keyword>Genetic diseases</keyword>
  <keyword>Inborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achondroplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

